查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2032741

2026-2034年全球難治性憂鬱症治療市場規模、佔有率、趨勢和成長分析報告

Global Treatment-Resistant Depression Treatment Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 129 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球難治性憂鬱症市場規模預計將從2025年的30.8億美元成長至2034年的80.3億美元，2026年至2034年的複合年成長率（CAGR）為11.23%。該市場呈現強勁成長勢頭，主要原因是全球難治性憂鬱症盛行率持續上升。難治性憂鬱症患者對傳統抗憂鬱症藥物治療反應不佳，因此需要更先進的替代療法。人們對心理健康的日益關注以及憂鬱症負擔的加重是推動市場需求的主要因素。

該市場的成長主要得益於治療方法的創新，包括新型藥物療法、神經調控技術和心理治療方法。速效抗憂鬱症和氯胺酮治療方法的引入顯著改善了治療效果。此外，旨在意識提升的醫療保健投入增加以及政府的支持措施也促進了市場成長。

隨著研究不斷致力於開發更有效、更個人化的治療方法，該市場的未來前景極為光明。腦刺激技術和數位療法的進步將進一步改善患者照護。人們對心理健康治療的接受度提高以及社會偏見的減少，將鼓勵更多人尋求幫助。隨著對有效解決方案的需求持續成長，難治性憂鬱症的治療市場預計將顯著擴大。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節提供清晰的市場概覽，包括關鍵定義、分類和當前產業格局。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分依據產品類型、應用、最終使用者和地區，將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭動態以及主要參與者所採取的策略。

市場預測：本預測是基於特定預測期內的市場規模和成長模式數據。本節結合歷史趨勢、當前市場狀況和定量分析，揭示未來預期趨勢。

區域分析：本部分全面回顧了主要地理區域的市場表現，確定了高成長領域和區域趨勢，從而更深入地了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的客製化服務，可根據您的具體需求自訂報告。這包括額外的細分、特定國家/地區的分析、競爭對手分析、客製化資料點或專注於特定細分市場的洞察，以更好地支持您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球難治性憂鬱症市場：依藥物類型分類

  • 市場分析、洞察與預測
  • N-甲基-D-天門冬胺酸（NMDA）
  • 抗憂鬱症
  • 抗精神病藥物
  • 其他

第5章：全球難治性憂鬱症市場：依通路分類

  • 市場分析、洞察與預測
  • 醫院藥房
  • 藥局和零售藥房
  • 網路藥房

第6章：全球難治性憂鬱症市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第7章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第8章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • GlaxoSmithKline
    • Pfizer Inc
    • Janssen Global Services LLC（Johnson & Johnson Services Inc.）
    • AbbVie Inc
    • AstraZeneca
    • H. Lundbeck A/S
    • Sandoz International GmbH（Novartis AG）
    • Par Pharmaceutical（Endo International Plc）
    • Otsuka Pharmaceutical Co. Ltd.（Otsuka Holdings Co. Ltd.）
簡介目錄
Product Code: VMR112110311

The global treatment-resistant depression treatment market size is expected to reach USD 8.03 Billion in 2034 from USD 3.08 Billion in 2025, growing at a CAGR of 11.23 during 2026-2034.This market is witnessing strong growth as the prevalence of Treatment-Resistant Depression continues to rise globally. This condition affects individuals who do not respond adequately to conventional antidepressant treatments, creating a need for advanced and alternative therapeutic approaches. Increasing awareness about mental health and the growing burden of depression are key factors driving market demand.

The market is driven by innovations in treatment modalities, including novel pharmacological therapies, neuromodulation techniques, and psychotherapy approaches. The introduction of fast-acting antidepressants and therapies such as ketamine-based treatments has significantly improved treatment outcomes. Additionally, increasing healthcare investments and supportive government initiatives aimed at mental health awareness are contributing to market growth.

Future prospects for this market are highly promising, with ongoing research focused on developing more effective and personalized treatment options. Advancements in brain stimulation technologies and digital therapeutics will further enhance patient care. Growing acceptance of mental health treatment and reduced stigma will encourage more individuals to seek help. As the need for effective solutions continues to rise, the treatment-resistant depression market is expected to expand significantly.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Drug Type

  • N-methyl-D-aspartate (NMDA)
  • Antidepressants
  • Antipsychotics
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

COMPANIES PROFILED

  • Eli Lilly and Company, GlaxoSmithKline, Pfizer Inc., Janssen Global Services LLC (Johnson & Johnson Services Inc.), AbbVie Inc., AstraZeneca, H. Lundbeck A/S, Sandoz International GmbH (Novartis AG), Par Pharmaceutical (Endo International plc), Otsuka Pharmaceutical Co. Ltd. (Otsuka Holdings Co. Ltd.).

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL TREATMENT-RESISTANT DEPRESSION TREATMENT MARKET: BY DRUG TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Drug Type
  • 4.2. N-methyl-D-aspartate (NMDA) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Antidepressants Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Antipsychotics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL TREATMENT-RESISTANT DEPRESSION TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Distribution Channel
  • 5.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Drug Stores & Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL TREATMENT-RESISTANT DEPRESSION TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

  • 6.1. Regional Outlook
  • 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.2.1 By Drug Type
    • 6.2.2 By Distribution Channel
    • 6.2.3 United States
    • 6.2.4 Canada
    • 6.2.5 Mexico
  • 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.3.1 By Drug Type
    • 6.3.2 By Distribution Channel
    • 6.3.3 United Kingdom
    • 6.3.4 France
    • 6.3.5 Germany
    • 6.3.6 Italy
    • 6.3.7 Russia
    • 6.3.8 Rest Of Europe
  • 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.4.1 By Drug Type
    • 6.4.2 By Distribution Channel
    • 6.4.3 India
    • 6.4.4 Japan
    • 6.4.5 South Korea
    • 6.4.6 Australia
    • 6.4.7 South East Asia
    • 6.4.8 Rest Of Asia Pacific
  • 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.5.1 By Drug Type
    • 6.5.2 By Distribution Channel
    • 6.5.3 Brazil
    • 6.5.4 Argentina
    • 6.5.5 Peru
    • 6.5.6 Chile
    • 6.5.7 Rest of Latin America
  • 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.6.1 By Drug Type
    • 6.6.2 By Distribution Channel
    • 6.6.3 Saudi Arabia
    • 6.6.4 UAE
    • 6.6.5 Israel
    • 6.6.6 South Africa
    • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

  • 7.1. Recent Developments
  • 7.2. Company Categorization
  • 7.3. Supply Chain & Channel Partners (based on availability)
  • 7.4. Market Share & Positioning Analysis (based on availability)
  • 7.5. Vendor Landscape (based on availability)
  • 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL TREATMENT-RESISTANT DEPRESSION TREATMENT INDUSTRY

  • 8.1. Top Companies Market Share Analysis
  • 8.2. Company Profiles
    • 8.2.1 GlaxoSmithKline
    • 8.2.2 Pfizer Inc
    • 8.2.3 Janssen Global Services LLC (Johnson & Johnson Services Inc.)
    • 8.2.4 AbbVie Inc
    • 8.2.5 AstraZeneca
    • 8.2.6 H. Lundbeck A/S
    • 8.2.7 Sandoz International GmbH (Novartis AG)
    • 8.2.8 Par Pharmaceutical (Endo International Plc)
    • 8.2.9 Otsuka Pharmaceutical Co. Ltd. (Otsuka Holdings Co. Ltd.)